A new kind of pill sharply reduced cholesterol in people at high risk of heart attacks despite taking statins.

By Atharva Singh and Arasu Kannagi Basil Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

The FDA said Friday that Merck's anti-COVID-19 pill is effective in treating the virus but said that regulators will meet next week to investigate whether the pill is safe for people who are pregnant ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...